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Abstract
A novel mechanism-based model - the Cancitis model - describing the interaction
of blood cancer and the inflammatory system is proposed, analyzed and validated. The
immune response is divided into two components, one where the elimination rate of ma-
lignant stem cells is independent of the level of the blood cancer and one where the
elimination rate depends on the level of the blood cancer. A dimensional analysis shows
that the full 6-dimensional system of nonlinear ordinary differential equations may be
reduced to a 2-dimensional system - the reduced Cancitis model - using Fenichel theory.
The original 18 parameters appear in the reduced model in 8 groups of parameters. The
reduced model is analyzed. Especially the steady states and their dependence on the
exogenous inflammatory stimuli are analyzed. A semi-analytic investigation reveals the
stability properties of the steady states. Finally, positivity of the system and the existence
of an attracting trapping region in the positive octahedron guaranteeing global existence
and uniqueness of solutions are proved. The possible topologies of the dynamical system
are completely determined as having a Janus structure, where two qualitatively different
topologies appear for different sets of parameters. To classify this Janus structure we
propose a novel concept in blood cancer - a reproduction ratio R. It determines the
topological structure depending on whether it is larger or smaller than a threshold value.
Furthermore, it follows that inflammation, affected by the exogenous inflammatory stim-
ulation, may determine the onset and development of blood cancers. The body may
manage initial blood cancer as long as the self-renewal rate is not too high, but fails to
manage it if an inflammation appears. Thus, inflammation may trigger and drive blood
cancers. Finally, the mathematical analysis suggests novel treatment strategies and it
is used to discuss the in silico effect of existing treatment, e.g. interferon-α or T-cell
therapy, and the impact of malignant cells becoming resistant.
1. Introduction
Formation of blood cells, hematopoiesis, takes place in the bone marrow
by cell division of hematopoietic stem cells (HSCs). Mutations of HSCs
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may lead to cancerous stem cells causing blood cancers, which ultimatively
suppress production of healthy blood cells [13, 21]. The myeloproliferative
neoplasms (MPNs) are disorders emanating from the bone marrow and pre-
dominantly consisting of chronic myelogeneous leukemia (CML), essential
thrombocythemia (ET), polycythemia vera (PV), and primary myelofibro-
sis (PMF) [11]. Despite similarities, common theoretical considerations can
be applied, since the diseases share clonal hematopoiesis as a hallmark and
are strongly influenced by - and coupled with - the inflammatory response
of the immune system [19].
In this article we develop a model of the system underlying the blood
cancer diseases coupled to the inflammatory response system. The model
presented in [2] is used as a starting point and only what is truly important
for the purpose af the model is included.
Most cancers are developed somewhat similarly in the early avascular
phase before tumor size plays a role [70, 71]. Thus, the present model
may be adapted for early cancer more generally despite it being developed
specifically for blood cancers. Some blood cancers are curable, while others,
such as MPNs, are more challenging [61, 1]. Thus, special attention will be
on MPNs although the frequency of getting MPNs is relatively low.
In [2] a novel and mechanism-based model of blood cancers coupled to
the inflammatory response of the immune system was proposed. The model
is to our knowledge the first of its kind and furthermore generic in the
sense that it describes blood cancer in general. Shortly after, Komarova
et. al. published a simplified approach to discuss the role of inflammation
in MPNs [72]. They include stem cell dynamics and bone marrow niche
feedback, but describe the inflammation as a fixed parameter independent
of the actual cancer development, i.e. independent of the immune response
to the cancer cells. This approach is somewhat similar to the 2-dimensional
approach taken in [24], where a simple model of stem cell dynamics includ-
ing bone marrow niche feedback, but without including inflammation, was
investigated.
In [2] T-cells were not explicitly considered, but in the present study we
include the effect of these. Accumulated evidence has indicated that the
immune system may recognize and eliminate malignant cells [52, 60] acting
as a control mechanism for maintaining homeostasis. This effect is called
immune surveillance, a concept attributed to Thomas and MacFarlane in
the late 1950s although a similar idea was promoted by Ehrlich already in
1909. Today it is refined into the concept of immunoediting [55].
An early mathematical model describing interaction of tumor cells and
effector cells (killer cells) for BCL1 lymphoma was presented by Kuznetsov
and Knott [41] continuing the work from [42], and was based on a logistic
growth equation to describe the intrinsic dynamics. Several models of the
role of inflammation in general cancer progression have since been studied.
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Most of these modeling attempts consider solid tumors and couples the T-
cell and natural killer (NK) cell dynamics to a logistic growth description
of tumors. The models in [54, 18, 53, 59, 17, 8, 34, 58, 28, 50, 51, 4, 32, 23,
3, 36, 5, 6, 48, 49] are simplified models describing how solid cancers may
stimulate the T-cells dynamics, while the cancer dynamics are decoupled
from the rest of the system, simply described as logistic growth or similar.
The works by Kuznetsov and Knott, Moore, Zhang et. al., Nanda et. al.
[41, 72, 48, 49] and the excellent books by Wodarz and Komarova [71, 38]
point toward the direction taken in the present paper.
Clapp et al (2015) [15] consider a 5D model including active and qui-
escent stem cells, progenitor cells, mature cells and one immune compart-
ment to describe chronic myelogenous leukemia. The active stem cell pool
is based on the logistic growth equation omitting interactions with the nor-
mal hematopoietic cells. Recently Besse et. al. (2018) [7] investigate a
simplified version of this model. Simultaneously Talkington et. al. (2018)
[65] compared four models of acute lymphocytic leukemia, namely those by
Kuznetsov et. al (1994) [42], Kirschner and Panetta (1998) [36], Dong et.
al. (2014) [22], and Moore and Li (2004) [48]. The purpose was to study
modified T-cells engineered to recognize CD19 surface marker clinically, re-
sulting in partial success in virtual treatment of the disease. All four models
predict a positive effect of the treatment. Historically, a few important mod-
els addressing tyrosine kinase inhibitors (TKI), e.g. imatinib, in treating
chronic myelogenous leukemia have appeared. Michor et. al. (2005) [46] ex-
plained incomplete eradication of CML under TKI treatment by resistance.
Komarova and Wodarz (2007) [37] incorporated quiescent stem cells and
the development of resistance to treatment. Using an agent-based model,
Roeder et al. (2006) [57] describe competition between leukemic stem cells
and normal hematopoietic stem cells and included the effect of TKIs on the
competition. Long-term effect of the immune response was modeled by Kim
et al. (2008) [35] by adding an unspecific immune component to the model
by Michor et al. (2005) [46].
Recently, Brady et. al. [9] suggested an inflammatory model coupled to
the autonomic regulation of the cardiovascular system for healthy subjects
exposed to intravenous injection of lipopolysaccharide (LPS) to stimulate
an inflammatory response. Simultaneously, Bangsgaard et. al. [6] suggested
a detailed inflammatory response model coupled to the Hypothalamic–
Pituitary–Adrenal axis allowing an exogeneous stimuli. This so-called ITIS
model contains eight time-dependent variables: Endotoxin, phagocytic cells,
pro- and anti-inflammatory cytokines (a broad category of signaling molecules
consisting of small proteins): TNF-α, IL-10, TGF-β, CRH, ACTH and cor-
tisol. The ITIS model is capable of reproducing available data and has
served as an inspiration in the present work, but in a suitable simplified
form.
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The outline of the paper is as follows. In section 2 the model is presented
and in subsection 2.1 it is expanded by explicitly including a description of
the interaction with immune response effector cells such as T-cells. The
model is put on a dimensionless form and based on a separation of time
scales, a two-dimensional model - the reduced Cancitis model - is suggested
in section 3. The reduced Cancitis model is analyzed in section 4. Admissi-
ble steady states are derived and in subsection 4.1 their stability properties
are examined depending on the external inflammatory stimuli. A complete
analysis of the topology of the dynamical system is presented, showing a
Janus topology1. An attracting trapping region is constructed in subsection
4.2 establishing global existence and uniqueness of solutions. A treatment
plan by T-cell gene therapy appear in subsection 4.3 along with a descrip-
tion of how the phase plane varies with increasing external inflammatory
stimuli. Special focus is on the role of the level of external inflammatory
stimuli and its effect on existence and stability of healthy and unhealthy
steady states of the model. The various findings are discussed and conclu-
sions made in section 5. Finally, some cumbersome derivations related to
the steady states are presented in Appendix A and Appendix B.
2. The model
As in the previous model presented in [2] focus will be on ensembles of
each cell type and not the individual cells. Hence, the governing laws will
be for the pools of cells, commonly denoted compartments. The compart-
ments encompass the healthy hematopoietic stem cells in the bone marrow,
the healthy hematopoietic mature cells in the blood, the malignant stem
cells in the bone marrow, the malignant mature cells in blood, the pool of
dead cells and the resulting debris not yet cleared, and a variable describ-
ing the immune system activity level, which correlates with the associated
cytokines related to the disease. In what follows we will denote healthy
hematopoietic cells shortly as hematopoietic cells in contrast to e.g. ma-
lignant cells. As we are aiming for an integrated mechanism-based model
for blood cancers, competition between cell types is crucial. The function
of the immune system to handle dead cells constitutes an effective feed-
back mechanism regulating the stem cell reproduction whereas the specific
T-cell response fights the cancer cells. The aggregated immune response is
known to correlate with the disease state of the blood cancer. Mathemati-
cally the dynamics is described by non-linear ordinary differential equations
respecting conservation laws as illustrated in figure 1.
1Named after the ancient Greek God Janus having two faces meaning that two dif-
ferent topologies exists.
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Figure 1: The conceptual model corresponding to equation (1). Light gray boxes
(symbolized x0, x1, y0, and y1 for the hematopoietic stem cells (HSC), the hematopoietic
mature cells (HMC), the leukemic stem cells (LSC), and the leukemic mature cells (LMC),
respectively) illustrate the compartments of the basic model and the black arrows the
rates of the flows between these compartments. Stem cells differentiating into progenitor
cells reduce the amount of these with rates ax and ay and enter the corresponding
mature cell-pools as these rates are multiplied by progenitor application factors (Ax
and Ay, respectively, and symbolized by ⊗-symbols). All cells may undergo apoptosis
and their death rates are indicated by black arrows labeled with a d index and the
corresponding variable. A normal hematopoietic stem cell may mutate into a malignant
stem cell with an effective probability rm indicated by a black arrow. The light blue
compartment (symbolized a) contains all dead cells and the light orange compartment
(symbolized s) the inflammatory level, i.e. the immune response. Blue arrows from these
represent related rates of flow: ea is the second order elimination rate of debris, es is
the elimination rate of the inflammatory activity, and rs is the rate by which dead cells
stimulate the inflammatory response. Red stipulated arrows (marked by (s)) going from
the inflammatory compartment represent effects of the cytokines (or neutrophils when
eliminating dead cells) modulating the rates of the basic model. The green stipulated
lines represent the bone marrow niche inhibition (depending on x0 and y0, see text)
modulating the self-renewal rates, rx and ry.
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Using symbols as in figure 1 and letting dot denote the time derivative,
the mathematical equations are,
ẋ0 = (rxφx(x0, y0)s− dx0 − ax)x0 − rmsx0 (1a)
ẋ1 = axAxx0 − dx1x1 (1b)
ẏ0 = (ryφy(x0, y0)s− dy0 − ay)y0 + rmsx0 (1c)
ẏ1 = ayAyy0 − dy1y1 (1d)
ȧ = dx0x0 + dy0y0 + dx1x1 + dy1y1 − eaas (1e)
ṡ = rsa− ess+ I (1f)
The time dependent variables x0, x1, y0, y1, a, and s denote the amount of
(healthy) hematopoietic stem cells (HSC), (healthy) hematopoietic mature
cells (HMC), malignant stem cells (LSC), malignant mature cells (LMC),
dead cells, and the cytokine level, an abstract quantity describing the ac-
tivity level of the immune system, respectively. Whenever cells undergo
apoptosis the debris has to be engulfed by phagocytic cells, e.g. neutrophils
and macrophages, which are regulated by the release of a hierarchic cas-
cade of pro- and anti-inflammatory cytokines [32, 23, 36]. Following the
parsimonious principle we let the dead cells (a) up-regulate the amount of
phagocytic cells (s) with rate constant rs, while they are eliminated with a
rate es. In addition endotoxins, smoking and other environmental factors
may add to the inflammatory response; thus we add a term (characterized
by the lightning symbol in Figure 1). Since MPNs develop on a time-scale
of years and inflammatory immune processes are on a time-scale of hours-
days ([12, 16, 14, 5]) we may assume a QSSA, implying that the ratio of
the amount of phagocytic cells and the cytokines are fixed. Thus, the cy-
tokine level is proportional to the phagocytic level and the inflammatory
compartment (s) represents both.
The dynamics of the hematopoietic stem cells (x0) are governed by the
self-renewal rate rx, the death rate dx0 , and the division into progenitor cells
with rate ax. The inhibiting niche feedback in the bone marrow, represented
by the function φx, controls cell division in a healthy individual and allows
for competition between healthy and cancerous stem cells when both are
present (see below). Furthermore, inflammation stimulates self-renewal and
is assumed to be proportional with the cytokine level. This reflects the fact
that an increase in hematopoietic cell death instigates the birth of extra
cells. Finally, the stem cells may mutate with a mutation rate rm, which
is believed to increase with inflammation [19, 10, 39, 33, 31, 30, 70, 68, 71,
72, 2, 29].
The dynamics of the malignant stem cells (y0) are governed similarly and
we use the same symbols with an y-index instead of an x-index to denote the
corresponding rates. The only difference is that mutation of hematopoietic
stem cells add to the number of malignant cells and is proportional to the
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number of hematopoietic stem cells. In addition, we will later allow the
death rate dy0 to be y0-dependent.
If no mutations occur, stem cells divide either into two stem cells of
the same type as the mother cell, into two progenitor cells, or divide into
one of each. Progenitor cells differentiate further into new and gradually
more and more mature progenitor cells in a number of generations (k) to
ultimately divide into fully matured cells (i.e. cells which do not divide
further). The progenitor cells are not explicitly considered in the model.
However, a stem cell dividing into two progenitor cells, so-called symmetric
division, will at the end give rise to A = 2k mature cells, which we denote
as the multiplication factor. Hence, the change in hematopoietic mature
cells per time becomes axAx times the amount of hematopoietic stem cells,
where we denote Ax the multiplication factor for the hematopoietic cells,
which in general is larger than 2k. Simultaneously, hematopoietic mature
cells undergo apoptosis with a constant rate dx1 .
Again, the change in malignant mature cells per time is similar to that
of the hematopoietic mature cells, but with index y instead of x.
The change in the amount of dead cells per time is given by the death
rates times the number of cells in the afore mentioned compartments minus
the clearing by the immune system. This clearing is taken to be a second
order equation in the number of dead cells and the of amount of cytokines,
representing the activity of the immune system, eliminating the dead cells
with an elimination rate ea.
The stimulation of the immune system is proportional to the amount of
dead cells with rate rs whereas the elimination is taken to be proportional
to the amount of cytokines with rate es. We emphasize that the immune
system is stimulated by an increased number of cancer cells by this feedback
mechanism. In addition we include the possibility of an exogene stimulation
of the immune system I(t), where we indicate that this stimulation may
change over time t. This exogene stimulation may be taken as anything
provoking the immune system, e.g. infections, smoking or pollution. In
many mathematical considerations we will take the inflammatory load I to
be piecewise constant to allow for analytical results.
Finally, the bone marrow niche feedback functions are in general de-
creasing functions of the individual stem cell types. We choose
φx = φx(x0, y0) =
1
1 + cxxx0 + cxyy0
(2a)
φy = φy(x0, y0) =
1
1 + cyxx0 + cyyy0
, (2b)
where cij describes the inhibitory strength of the signaling bone marrow
niche feedback from cell type j onto cell type i. It is generally assumed that
cyy ≤ cyx < cxy ≤ cxx, since leukemic cells are less sensitive to inhibitive
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niche feedback than healthy hematopoietic cells. Similar to [24] our investi-
gations show no qualitative difference in observed model output when using
various functional forms of the negative feedback.
Motivated by the biology where numbers of cells and concentrations are
required to be non-negative numbers, we will use the terminology that a
steady state is admissible if and only if all components are non-negative i.e.
if and only if the steady state is in the non-negative octahedron. We denote a
steady state as appropriate if and only if it does not require a degenerated
set of parameters, i.e. a set of parameters where an equality constrain is
imposed on the parameters whereas inequalities constrains are allowed. The
reason is that such a set of parameters are not robust to perturbations and
thus biologically unlikely to exist. However, non-appropriate steady states
may still be of interest since they divide possible situations of interest like
e.g. bifurcation points do.
In most considerations we take the mutation rate to be zero to ease the
analytical analysis. Hence, we start our system in a steady state related
to none malignant cells and introduce a single malignant stem cell initially.
Thus the initial condition will be that of a (healthy) hematopoietic steady
state except one malignant stem cell is added to that state.
The model stated in equations (1) and (2) is presented in [2] and will
be analyzed in detail elsewhere. For later use it is sufficient to know that
two admissible hematopoietic steady states (defined as one having y0 = 0,
but x0 6= 0) may exist depending on the level of exogenous inflammatory
stimuli I,







x0H±, y0H± = 0, y1H± = 0, aH± =
essH±−I
rs




















, and βx = axAx + dx0 . These steady state coordinates
will be used for turning the model into proper dimensionless form.
2.1. Model extension: Including the T-cell response
Whenever cells die, the debris have to be engulfed by phagocytic cells,
e.g. neutrophils and macrophages and are regulated by a hierarchic cascade
of pro- and anti-inflammatory cytokines are released. Apoptosis is mediated
by the immune system and is included in the Cancitis model. The immune
response may be split into two parts namely the innate immune response and
the adaptive immune response [45]. The innate immune response provides
an immediately but non-specific response. The innate response consists of
granulocytes, dendrites, macrophages and natural killer cells. The adaptive
immune response is activated by the innate immune response. Thus a delay
is introduced from exposure to maximal response and this delay may be
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Table 1: Default parameter values (rm = 0) from [2]
Parameter Value Unit Parameter Value Unit
rx 8.7 · 10−4 day−1 ry 1.3 · 10−3 day−1
ax 1.1 · 10−5 day−1 ay 1.1 · 10−5 day−1
Ax 4.7 · 1013 - Ay 4.7 · 1013 -
dx0 2 · 10−3 day−1 dy0 2 · 10−3 day−1
dx1 129 day
−1 dy1 129 day
−1
cxx 5.6 · 10−5 - cyx 5.2 · 10−5 -
cxy 5.4 · 10−5 - cyy 5.0 · 10−5 -
es 2 day
−1 rs 3 · 10−4 day−1
ea 2 · 109 day−1 I 7 day−1
up to 7 days [45]. The adaptive immune response includes B-cells and T-
cells also denoted lymphocytes. We include naive T-cells and effector
T-cells, since these have an important role in inhibiting the development of
cancer [43]. Effector T-cells are responsible for a direct defense, where they
induce death to the malignant cells. Naive T-cells are activated by antigen
presenting cells (APC). A QSSA suggests itself, since we are interested in
the time-scale of years and the time-scale of the adaptive immune response
is of order days.
The presence of foreign antigens in the body may be sensed by the naive
T-cells (Tn). This will start a cascade of up-regulating cells and molecules in
the immune system, among these effector T-cells (Te), e.g CD8
+ T-cells, and
NK-cells. These specifically attack and destroy the identified foreign cells
(necrosis). The process from identification to attack happens on a time-
scale of a week, however, the effector cells have memories to recognize the
identified cells afterwards. This process is known as immune surveillance.
Inspired by Moore and Natasha [48, 49], we let the naive T-cells identify
the cancer cells (we let temporarily y denote the number of such, which in
our case will be y0 or y1). These T-cells are transformed into effector cells
proportional to the product of the number of naive T-cells and cancer cells
with rate, kn. Naive T-cells may produce αn effector cells per transforming
naive T-cell. A linear elimination of naive T-cells appear simutaneously
with rate ηkn. The naive T-cells are produced at a constant rate pn, whereas
effector cells are eliminated proportional to Te with rate γe. Thus,
Ṫn = pn − knTn(y + η) (4)
and
Ṫe = αnknTny − γeTe. (5)
The pool of effector cells (Te) eliminate the cancer cells as a second order
reaction with rate γy. Letting ’growth’ denote the aforementioned dynamics
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of cancer cells without explicitly including the T-cells, i.e. the right hand
side of equation (1c) or (1d), the governing equation of malignant cells
become
ẏ = growth− γyTey. (6)
The fast T-cell response compared to the slow timescale of MPNs develop-
















and where the approximation holds if y  η. Hence, using
the approximation in equation (8) the death rate dy in the ’growth’ part
may be substituted by
dy → d̂y + d̃y
η y
η + y
≈ d̂y + d̃y · y (9)
for y  η where d̂y = dy. Thus, the constant mortality rate is changed by
adding a death rate which is linear in y. In fact, this may be considered as a
general approximation of a possible y-dependent death rate by its first order
Taylor expansion. We emphasize that this expression is desirable, since it
is still simple, but includes an important effect for non-vanishing values of
y. A reasonable choice is to take d̂y = dy0 and d̃y ∼ 10−6 day−1 as default
values. These estimates are based on requiring the two elimination terms
to be of the same order and equal to that for normal hematopoietic stem
cells, which is approximately 0.002 cell per day [20, 2].
Hence, the leukemic model in equation (1) still holds with dy0 substituted
by d̂y0 + d̃y0 ·y0 where we assume that the most important effect is on the
stem cell compartment, which drives the cancer development. The previous
analytical results obtained are corrupted by the extension allowing the death
rate to be y0 dependent. We therefore seek a suitable model reduction
(obtained in equation (10)) allowing a more thorough analysis.
2.2. Model validation
In the stable hematopoietic steady state the numbers of stem cells and
mature cells are taken to be approximately 104 and 4 · 1010, respectively,
which are compromises between reported values [26, 27, 25, 62, 63, 20]. In
the final stage of full blown cancer, the number of hematopoietic cells is
vanishing and the cancer cells will approach a stable steady state with a
higher amount of cells than in the healthy steady state. The absolute val-
ues are more uncertain but we have aimed for 105 cancer stem cells and 1013
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mature cancer cells as reported in [20]. In clinical practice JAK2V617 allele
burden and the total cell count in the blood are usually measured. Whereas




The JAK2V617 allele burden has been reported to have median values of
7% ( 95% CI 2-15% and range 1-39%), 33% ( 95% CI 20-40% and range
1-92%), and 67% ( 95% CI 52-95% and range 37-99% ) in ET, PV and
PMF patients, respectively [44]. The model is calibrated to resample this
dynamic in the JAK2V617F allele burden, which gives predictions, tET ,
tPV , and tPMF for when ET, PV and PMF appear, respectively. For il-
lustrations of cell counts and allele burden see Fig. 2 Cytokines as IL-1β,
IL-1RA, IL-2R, IL-6, IL-8, IL-10, and IL-12 are considered to be specific
indicators of the inflammatory level during MPN, whereas C-reactive pro-
tein (CRP) is a general inflammation biomarker. All these have been shown
to correlate with MPN states ET, PV and PMF. [66, 67] Thus we assume
linear correlations between each of these and the inflammatory level s. In
addition LDH values, which express the total rate of dying cells per time
(D = dx0x0 + dx1x1 + dy0y0 + dy1y1) were demonstrated to be correlated to
the MPN states ET, PV and PMF [44]. The model outputs are compared
to the data in Fig. 3. using the estimated instances tET , tPV , and tPMF for
ET, PV and PMF, respectively. The model predictions are in a remarkable
accordance with the data.
3. The reduced Cancitis model
The extended model is brought into dimensionless form by scaling the
variables of the model. A time scale separation argument is used to obtain a
reduced model, corresponding to setting the time derivative of x1, y1, a, and
s to zero. The four dependent variables may then be solved in terms of x0
and y0. As this approach is well known and straightforward, the derivation
is shown in appendix Appendix A. Analyzing the resulting equations (10) in
terms of the scaled hematopoeitic stem cells, X0, and the scaled cancerous
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∼ 10−1, and 2By =







∼ 10−1. Notice, the ratio between Bx and
11
Figure 2: Left: Typical development in stem cells (top left) and mature cells (bottom
left). Healthy hematopoietic cells (full green curves) dominate in the early phase where
the malignant cells (stipulated red curves) are few in number. The total number of cells
is also shown (dotted black curves). When a stem cell mutates and escapes repairing
mechanisms, it approximately starts a slowly increasing exponential growth (at t = 0).
At a certain stage the malignant cells become dominant and the healthy hematopoietic
cells begin to show a visible decline. Finally, the competition between the cell types
results in a takeover by the malignant cells, leading to an approximately exponential
decline in the amount of normal hematopoietic cells and ultimately their extinction. The
development is closely followed by the mature cells. Right: The corresponding allele
burden (7%, 33% and 67% corresponding to ET, PV and PMF, respectively, shown as
blue columns) defined as the ratio of MPN mature cells to the total number of mature
cells. The full green curve illustrates the continuous model prediction. Default parameter
values from table 1 and 2 have been used.
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Figure 3: Model validation. Cytokines from upper left to lower right; IL-1β, IL-1RA,
IL-2R, IL-6, IL-8, IL-10, IL-12 as well as the plasma concentration of C-reactive protein
(CRP) are approximatively linearly correlated with the inflammatory level s, whereas
lactic dehydrogenase (LDH) is linearly correlated with and compared to the total amount
of dying cells per time D = dx0x0 + dx1x1 + dy0y0 + dy1y1. On each subplot data are
shown (red dots encircled by black) at predicted times for ET, PV and PMF (left to
right) estimated from the allele burden in Fig.2. On each subplot model predictions are
shown (full green curve). Default parameter values from table 1 and 2 have been used.
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By is the ration between the rate by which the corresponding mature cells
are produced normalized by their self-inhibitory factor (carrying capacity).
The default dimensionless parameter values are listed in table 2. Note,
the reduced model involves 8 parameters where D1 describe the strength of
the Y0 dependent elimination term in dimensionless form. The numerator
in equation (10) corresponds to the scaled cytokine level and the denom-
inators express the stem cell niche interactions allowing for different com-
petitive advantages of hematopoietic and cancerous cells. The death rate
of hematopoietic stem cells has been normalized to 1, whereas a different
rate is allowed for cancer stem cells (D0) as well as an extra degradation
term (D1Y0) corresponding to the T-cell response. We emphasize the local
existence and uniqueness of solutions in the non-negative octahedron. Sub-
sequently we will focus on the impact of the dimensionless inflammatory
stimuli J .
Table 2: Default dimensionless parameter values (rm = 0)
Parameter Value Parameter Value
R 1.49 J (baseline) 0.76
D0 1.00 D1 0.10
Cx 0.93 Cy 1.08
Bx 0.06 By 0.07
Figure 4 illustrates that the reduced cancitis model agrees excellently
with the full model for various values of D1. As seen, an increase in the Y0-
dependent death rate, corresponding to how aggressively the effector cells
eliminate the malignant stem cells, conjures a bearable co-existing state.
Higher values of D1 yields a lower burden of malignant cells. This is in ac-
cordance with the concept of immune surveillance (as illustrated in figure 4
for D1 = 5), [55]. If resistance appears, i.e. the malignant cells become
immune to the effector cells, it agrees with the concept of immunoediting
[55]; In the first phase malignant cells are killed (not pictured in figure 4),
in the second phase a pseudo-equilibrium between immune and malignant
cells appears (as for D1 = 5 in figure 4), and finally the third phase - the
escape phase - develops, where the co-existing pseudo-steady state disap-
pears due to an absence of a sufficient immune response. In the escape
phase the disease ultimately gives symptoms and it may become clinically
detected (as for D1 = 0.1 in figure 4). The absence of a sufficient im-
mune response is believed to be caused by a down-regulation or loss of an
expression of malignant antigens, an upregulated resistance of malignant
cells, an increased expression of pro-survival genes, or the development of
an immunosuppressive malignant cell microenvironment. [55]
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Figure 4: Comparison of the reduced model (stipulated curves) and the full model (full
curves) for dimensionless values D1 = 0.1, 0.5, 1, 5. Green curves show hematopoietic
stem cell counts and red curves show malignant stem cell counts versus time in years.
All quantities are in dimensional variables.
4. Analysis and results
We study the effect of the dimensionless inflammatory load J on the
possible steady states and their stability for the reduced cancitis model in
equation (10). Thus, we start by investigating the existence of steady states.
By definition
• A trivial steady state is defined as having X0 = Y0 = 0.
• A (purely) hematopoietic steady state is defined as having Y0 = 0,
but X0 > 0.
• A (purely) leukemic steady state is defined as having X0 = 0, but
Y0 > 0.
• A co-existing steady state is defined as having X0 > 0 and Y0 > 0.
Note, non-negativity of X0 and Y0 implies non-negativity of the derived
variables X1, Y1, A, and S+ given by equation (A.9). Straight forward,
but tedious computations (see Appendix B) give analytical results for the
steady states, which are summarized as,
• An admissible trivial steady state always exists,
F0 = (0, 0). (11)
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− 1 = 0 , (12)
with X0H > 0. For certain combinations of parameter values two
solutions may exist,
X0H± = J +Bx − 1±
√
(J +Bx − 1)2 + 2J − 1 . (13)
For FH± to be admissible all components have to be real and non-
negative and X0 have to be positive. This gives rise to some re-
strictions given as inequalities in the level of exogenous inflammatory
stimuli.
– For Bx <
1
2
no admissible hematopoitic steady state exists for
J ≤ 1
2
. A bifurcation happens at J = 1
2
such that for J > 1
2
a unique, admissible hematopoetic steady state, X0H+, exists
with X0H+(J)→ 0 for J → 12 and X0H+(J) being an increasing
function.
Note, both the existence and the value of X0H+ only depends on the
two parameters J and Bx. Remarkably, increasing the dimensionless
rate Bx ≈ rscxxesea , by which the normal cells stimulate the dead cell
pool, leads to an increase in the amount of normal cells X0H+ at the
hematopoietic steady state value.







−D0 −D1Y0 = 0 , (14)
with Y0L > 0.




a unique, admissible leukemic steady state exists.
Then Y0L(J) is increasing in J .















no leukemic steady states
exist.


















leukemic steady state is created. This happens as Y0(J) increases
from 0 with increasing J .
Note, both the existence and the value of a leukemic steady state only













































Candidates for Y0C are solutions to a fourth order polynomial with
intricate expressions for the coefficients not easily investigated ana-
lytically. The co-existing steady state is not created by a bifurcation
through (0, 0) as no solution to (15) and (16) exists for (X0C , Y0C) ap-
proaching this point. Instead the co-existing steady state bifurcates
from either the hematopoietic or the leukemic steady state, depending
on the stability properties of these.
4.1. Stability considerations
In this section we examine the stability properties of the various admis-
sible steady states of the reduced model. The stability of the steady states
are equivalent to the stability of the linearized equations near the steady
state, if the steady state is hyperbolic, i.e. if no eigenvalue of the matrix
of the linearized system has real part equal to zero. The Jacobian, J , of
equation (10) is computed analytically at most of the steady states, see be-
low. Thus, for these steady states, the eigenvalues of the linearized system
are easily obtained analytically and otherwise numerically. If all eigenvalues
have negative real part, the steady state is stable and attracts neighbouring
solutions, while if at least one eigenvalue has positive real part, the steady
state is unstable. For the trivial steady state, the leukemic steady state and
the hematopoietic steady state, J is calculated analytically and becomes
triangular, thus the eigenvalues can be directly read off from the diagonal.
In this section we focus on cases that may be investigated analytically

















which were also used in the previous section for clear statements on exis-
tence of a hematopoietic and a leukemic steady state, respectively. In the
following we investigate the stability of the steady states.
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First, consider the trivial steady state. At F0 the Jacobian for the











with eigenvalues λ1 = J− 12 and λ2 = J−
D0
2R
. Evidently the two eigenvalues




}. Compared to the previous section
this implies that the trivial steady state is stable only if there are no leukemic
or hematopoietic steady states.
Secondly, consider the hematopoietic steady state and the corre-








JH(1, 2) = X0H+









J2 + 2BxX0H+ (1 +X0H+)
2 .
(21)
The Jacobian is an upper triangular matrix with vanishing entry (2,1),
i.e. JH(2, 1) = 0, and the eigenvalues are given by the diagonal entries.
The first eigenvalue λH1 = JH(1, 1) has corresponding eigenvector pointing













Whenever the hematopoietic steady state is admissible, X0H+ > 0 corre-
ponding to J > 1
2
, the eigenvalue is negative, λH1 < 0. Thus, if the dynamics
is restricted to the X0-axis then X0H+ is stable. This is a desirable prop-
erty of the model as it illustrates that homeostasis is maintained prior to a
mutation providing a malignant stem cell.









As X0H+ does neither depend on Cx nor
D0
R
a direct inspection of equation
(23) yields that increasing Cx or
D0
R
has a stabilizing effect.













Cx ≥ 1 then 1+X0H+1+CxX0H+ ≤ 1. Hence, if
D0
R
> 1 and Cx ≥ 1, which corresponds
to the malignant cells are inhibited more than the hematopoietic cells by the
niche feedback, then the hematopoietic steady state is stable for arbitrarily
large X0H+. For Cx <
R
D0
< 1, the stable hematopoietic steady state will
turn unstable for sufficiently large J , since λH2 approaches C
−1
x − D0R > 0
as X0H+ increases unboundedly with J . Rewriting λH2 = 0 by use of




J2 + 2BxX0 + 2ByY0
1 + CxX0 + Y0
−D0 −D1Y0 = 0 (24)
at Y0 = 0 corresponding to the coexisting steady state being extended to
the Y0 axis (see expression (16)). This means that the hematopoietic steady
state changes stability when it crosses a branch of the co-existing steady
state on the X0-axis and is unstable for large values of X0H+ corresponding










As X0H+ is an invertible function of J , equation (25) may be expressed as
a threshold value of J ,
Jc =
X2c + 2(1−Bx)Xc + 1
2(1 +Xc)
. (26)









JL(2, 1) = RY0L








J2 + 2ByY0L (1 + Y0L)
2 .
(28)
The Jacobian is a lower triangular matrix. Since entry (1,2) vanish, JL(1, 2) =
0, the Y0-axis is the eigenvector direction for the eigenvalue λ2 = JL(2, 2)
evaluated at the leukemic steady state. Using the restrictions on By from












≤ −D1Y 20L , (29)
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− 1 . (30)









λL1 > 0 if
D0
R




. Increasing Cy has a stabilizing
effect by decreasing λL1. Contrary to the hematopoietic case, an initial
negative λL1 will inevitably become positive for increasing J , after which
Y0L increases unboundedly causing the first term in equation (30) to become
larger than one. The analytical results for existence and stability of the
trivial, hematopoietic and leukemic steady states are summarised in figure
5.
Lastly, consider the co-existing steady state. The admissible co-
existing steady states are calculated numerically as a function of J and so
is the Jacobian and its eigenvalues using the parameter values in table 2 for
the remaining parameters when nothing else is specified. The results are
summarized in figure 8 and admissible co-existing steady states are stable
for J > 3.636 approximately. The model implies that the ratio between R
and the cell death rate D0 is important. If the ratio between D0 and R is
less than one, the leukemic steady state is stable when created and occurs
before the unstable hematopoietic steady state occurs for J increasing until
the co-existing steady state may take over the stability and bifurcate from
the leukemic steady state. This is not to say that an increase in the in-
flammatory load cures the in silico patient or that it reduces the impact of
the disease. Instead the co-existing steady state level of the malignant cells
saturates approximately at the level as the level of malignant cells at the full
leukemic steady state at the bifurcation point. Thus the tumor burden is
not decreased, but is only prevented from increasing significantly. See Fig 6
and 8. This model based hypothesis may seem a little counter-intuitive
and deserves clinical testing. Conversely if, the ratio between D0 and R is
larger than one, the hematopoietic steady state is born stable and occurs
before the unstable leukemic steady state occurs for J increasing until the
co-existing steady state may take over the stability of - and bifurcate from
- the hematopoietic steady state, see figure 7. Hence we emphasize that the
dynamics of the system is rather different depending on whether the ratio
between D0 and R is less than or greater than one. Thus increasing the ratio
D0 to R or increasing the ratio of D1 to R, as illustrated in Fig. 7, represent
very appealing candidates for treatment. Equation (B.11) is equivalent to
equation (B.18) with X0 = 0, thus the leukemic steady state and the co-
existing steady state equals for X0 = 0. By the implicit function theorem
it follows that for Y0 ≥ Y0L the derivative of X0 = X0(Y0) with respect to
Y0 is positive corresponding to an increasing steady state trajectory in J .
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Figure 5: Phase plane diagram for the hematopoietic cells (X0) and the leukemic cells
(Y0). The cases corresponding to analytical results of the trivial, hematopoietic and
leukemic steady states and their stability are shown. J increases from top row to bottom
row illustrating the sequence of bifurcations for increasing J in the two cases D0R > 1
and D0R < 1. Full circles are stable steady states, open circles are unstable steady states.
The black dotted line is the boundary of the analytical trapping region, the red curve is
nullcline of Ẏ0, and the green stipulated curve is the nullcline of Ẋ0. In the left column the
hematopoietic steady state is stable independently of the presence of a leukemic steady
state whereas in the right column, the leukemic steady state is stable. We emphasize
that the trapping region generally depends on D0 and J as well as R,Bx, By, Cx, and
Cy. On some subplots the dotted black line lies outside the visible rage.
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The possible topologies are summarized in figures 6 and 7. The corre-
sponding bifurcation diagram are depicted in figure 8. Continuous anima-
tions for varying J for different fixed values of D0 and D1 may be found
at http://dirac.ruc.dk/cancitis/ together with an animated bifurcation di-
agram (see subsection 4.3 for further discussions). We refer to the topology
of the dynamical system as Janus topology, since it has two faces, i.e. two
different topologies for different set of parameters.
4.2. Existence af an attracting trapping region for the reduced cancitis model
A trapping region is a compact set with the property that orbits start-
ing in the trapping region cannot escape the region. An attracting trapping
region is a trapping region which is attracting, i.e. orbits starting outside
the trapping region will enter the trapping region (in finite time). An at-
tracting trapping region is a suitable feature for a biological system, since
it guaranties some basic well-behavior of the system such as boundedness
of solutions and global existence in time [56].
An attracting trapping region exists in the non-negative octahedron for
the reduced cancitis model in equation (10) (will be shown below). As a
consequence the steady states lies in this trapping region.
For some parameter values, X ′0 < 0 and Y
′
0 < 0 for any X0 and Y0. The
idea is to show that X ′0 < 0 and Y
′







2By} and L = min{1, Cx, Cy} . (31)
Thus, J2, 2Bx, 2By < K
2 and 1, Cx, Cy > L, which implies
J +
√
J2 + 2BxX0 + 2ByY0
1 +X0 + CyY0




1 +X0 + Y0
1 +X0 + Y0





J2 + 2BxX0 + 2ByY0







1 +X0 + Y0
1 +X0 + Y0
−D0 (33)




1 +X0 + Y0
1 +X0 + Y0




1 +X0 + Y0 . (35)
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Figure 6: Illustration of the dynamics in a (X0, Y0)-phase plane. Each row corresponds
to D1 = 0.1, 1, 10, respectively, whereas each column corresponds to J = 0.60, 0.76, 0.90,
respectively. Red curves are Y0 null clines (includes the X0-axis) and blue stipulated
curves are X0 null clines (includes the Y0-axis). Open circles represent unstable steady
states whereas full circles represent stable steady states. The black circle is the trivial
steady state, the green circle the hematopoietic steady state, the red the purely leukemic
steady state, and cyan the co-existing steady state. The attracting trapping region is
indicated on each palette by the coordinate axis and a black dotted line, which increases
with J but has slope -1 (the black dotted line may fall outside the visible range on some
subplots). The flows are indicated by the normalized slope field with arrows.
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Figure 7: Illustration of the dynamics in the (X0, Y0) phase plane. Each row
corresponds to D0 = 1, 1.52, 1.8, respectively, whereas each column corresponds to
J = 0.60, 0.76, 0.90, respectively. R is set to its default value 1.49. Red curves are
Y0 nullclines (and include the X0-axis) and green stipulated curves are X0 nullclines
(and include the Y0-axis). Open circles represent unstable steady states whereas full cir-
cles represent stable steady states. The black circle is the trivial steady state, the green
circle the hematopoietic steady state, the red circle the purely leukemic steady state, and
the cyan circle the co-existing steady state. The attracting trapping region is indicated
on each palette (surrounded by the coordinate axis and a black dotted line, which may
fall outside the visible rage). The trapping region decreases with D0 and increases with







Figure 8: Left column shows the bifurcation diagrams for the case D0R > 1 and the right
column shows the corresponding for D0R < 1 (the default case). The bifurcation diagrams
showing the appearance and stability of the admissible steady states depending on the
bifurcation parameter J . The top panel shows X0, the middle panel shows Y0, and the
lower panel shows the J-trajectory of the admissible steady states in a (X0, Y0) phase
plane having the range on the axis as in the other figures above. Green curves are the
hematopoietic steady states, red curves are the purely leukemic steady states, and cyan
curves are the co-existing steady states. At the origin a trivial steady state always exists.
It is stable for some values of J and unstable for others thus it is not shown on the figure.
Dotted curves mean that the corresponding steady state is unstable, while full curves
indicate that the corresponding steady state is stable. For the left column J ∈ [0; 4],
while for the right column J ∈ [0; 10].
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As X0 and Y0 are non negative, the minimal, allowed value of z is 1. Ex-
pression (34) is negative if and only if
z2 − αz − α > 0 . (36)






















Solving for X0 + Y0 this implies that the bound M is
M = z2crit − 1, (38)
i.e. for X0 + Y0 > M are X
′
0 < 0 and Y
′











Thus, M ≥ 0 and the triangle defined by the X0-axis, the Y0-axis and the
line X0 + Y0 = M thus define an attractive trapping region for equation
(10) . We emphasize that M generally depends on D0 and J as well as
R,Bx, By, Cx, and Cy.
4.3. Phase plane analysis and treatments
In the present work we mainly focus on analyzing the impact of the
inflammatory stimuli J , modifying the T-cell independent death rate D0,
and modifying the T-cell response represented by D1 rather than a com-
plete analysis of real treatments. However, several treatment scenarios are
possible, e.g. T-cell therapy. Interferon-α treatment among other things
stimulates the immune system, whereby the effect of the effector T-cells
become strengthened.
The reduced model has been investigated numerically for various choices
of parameters. The default parameters, as given in table 2, have been used
when nothing else is stated.
First consider the default case D0
R
< 1 as illustrated in figure 6 showing
the phase plane for various J and D1. A trivial steady state F0 is found to
always exist, and, for sufficiently low inflammatory stimuli J , it is stable.
For J greater than D0
2R
, a purely leukemic steady state FL becomes admissible
and the leukemic cells increase in numbers with increasing J . For choices of
J where only FL and F0 are admissible, the leukemic steady state is found
to be stable, whereas the trivial state is unstable. It is worth emphasizing
that the purely leukemic steady states in general only depend on the four






, By, and J .
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For J greater than 1
2
, an unstable hematopoietic steady state, FH+, be-
comes admissible. In absense of mutations, i.e. no malignant cells present,
the hematopoietic steady state appears stable. Being a saddle point with
stable manifold along the X0-axis and the unstable manifold having a non-
vanishing Y0-component, a perturbation with malignant cells may cause
the state to be repelling away from the hematopoietic steady state. As was
shown analytically, FH+ only depends on the two parameters J and Bx and
for fixed Bx, X0H+ increases with J .
As shown in figure 6, an admissible co-existence steady state, FC may
exist, which is dependent on both J and D1. While it has been found to ex-
ist for sufficiently high J , regardless of realistic values of D1, the existence of
FC does require very large values of J for D1 ≤ 0.1. For default parameter
values (e.g. D1 = 0.1) the co-existing steady state occurs for J larger than
Jc given by equation (26). The co-existing steady state is stable and bifur-
cates from the leukemic steady state which loses its stability and becomes
unstable. For increasing J , FC moves away from FL with increasing X0.
For D1 around 1 or greater, the co-existence steady state might represent a
possible preferable situation to the full-blown leukemic state FL. For large
choices of D1, such as D1 = 10 shown in figure 6, FC is in close proxim-
ity of FH+ for most realistic choices of J , leading to a co-existence steady
state, which can be interpreted as having a small number of leukemic cells,
which are held back from increasing due to a strong T-cell response. In the
case where the co-existence steady state exists, it is found numerically to be
stable, while the leukemic steady state FL becomes unstable whenever the
co-existing steady state becomes admissible. Thus, for any situation where
a co-existence steady state is admissible, the system will move towards this
state.
Increasing By, D0 or D1 and decreasing R cause the leukemic steady
state to appear at higher values of J while increasingBx causes the hematopoi-
etic steady state to occur for lower values of J . Thus, the model identifies
important parameters for potential protection to prevent a leukemic out-
break.
Next, consider the case D0
R
> 1 in contrast to the default case. Phase
plane portraits are shown in figure 7 for various J and D0. The situation is
analogous to the default case except the order in which the hematopoietic
steady state and the leukemic steady state occur are interchanged along with
their stability properties. Thus the hematopoietic steady state bifurcates
from the trivial steady state and takes over the stability for increasing J
shown in the second and third row of figure 7. For larger J-values the
leukemic steady state bifurcates from the trivial one as an unstable steady
state and it remains unstable for larger J . For even larger values of J the
co-existing steady state bifurcates from the hematopoietic steady state and
it takes over the stability leaving the hematopoietic steady state unstable.
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Figure 9: An in silico treatment of a virtual patient having (D1, J)=(1,0.9). The treat-
ment combines gene therapy, by increasingD1 to 10, and an anti-inflammatory treatment,
by lowering J from 0.9 to 0.76. Hereby the virtual patient is moved from a co-existing
steady state (upper cyan dot) with high malignant cell counts, (X0, Y0)=(0.27,0.55) cor-
responding to (D1, J)=(1,0.9), toward a co-existing steady state (lower cyan dot) with
low malignant cell count and normalized hematopoietic cell count, (X0, Y0)=(0.51,0.05)
corresponding to (D1, J)=(10,0.76). This treatment path (stipulated black curve) do not
follow the displayed slope field. Thereafter treatment is put on pause and the virtual pa-
tient follows the flow back toward the original co-existing steady state (full black curve),
(X0, Y0)=(0.27,0.55). Full red lines show the Y0 nullcline and the stipulated green lines
show the X0 nullcline. The open circles illustrate the unstable steady states (black for
the trivial, red for the leukemic, and green for the normal hematopoietic steady state).
The black dotted lines bound the region, which represents the total leukocyte count con-
sidered to be normal. Above the upper boundary the risk of thrombosis is considered
high and below the lower boundary the immune system is considered to be dysfunctional.
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For increasing J it slowly moves away from the hematopoietic steady state.
Compared to the default case, D0
R
< 1, this is not necessarily lethal, since
X0C stays relatively close to X0H and Y0C  Y0L.
Returning to the case D0
R
< 1, a scenario of an in silico treatment of a
virtual patient having (D1, J) = (1,0.9) is illustrated in figure 9. The treat-
ment combines a strengthened T-cell effect (interferon or T-cell therapy)
by increasing D1 to 10 and an anti-inflammatory treatment, which lowers
J from 0.9 to 0.76. Thus, the virtual patient is moved from a co-existing
steady state with high malignant cell counts, (X0, Y0)=(0.27,0.55) towards
a co-existing steady state with low malignant cell counts and normalized
hematopoietic cell counts, (X0, Y0)=(0.51,0.05). This treatment path (stip-
ulated curve) does not follow the displayed slope field shown, correspond-
ing to (D1, J)= (1,0.9). It takes approximately 5 years for the treatment
to lower Y0 to 15%, but almost 20 years to increase X0 to near normal
amount. The total cell count (X0 + Y0) is fairly well controlled during this
treatment process, which is essential to prevent high risk of thrombosis.
Thereafter treatment is put on pause and the virtual patient follows the
flow back toward the original co-existing steady state, (X0, Y0)=(0.27,0.55).
It takes about 20 years for Y0 to pass 0.5 corresponding to 10% below the
original amount. The time interval of treatment and relapse are both quite
large and it is likely that the malignant cells develop resistance during such
time span. On the other hand these time scales are comparable to clinical
experiences.






of malignant stem cells drives the development of resistance. Furthermore,
we assume that resistance inhibits the Y0-dependent death rate D1 by a
decreasing Hill-function in the exposure, as it is associated with a reduced
T-cell elimination of the malignant cells. Thus, the death rate, D1, in




We note that, as exposure increases, the effective death rate in equation (41)
decreases, leading to an increase in Y0, which further increases exposure and
so on. Initially, the development will be like that seen for the co-existing
steady state (as shown in figure 4 for D1 = 5), but as the exposure in-
creases, resistance develops and the dynamic starts to deviate from that
without resistance. Thus, after approaching the co-existing steady state
for a while the cancer development begins to increase approximately as
an exponential-function (for the second time) before finally reaching the
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saturation level, corresponding to full blown cancer, as seen in figure 10.
Meanwhile the hematopoietic cells show a reciprocal development. Overall,
the co-existing stable steady state is approached in the first phase of the
development, while resistance develops. When resistance becomes influen-
tial, around year 30, the co-existing steady state disappears and in the next
phase the full blown cancer develops. Thus, the developed resistance de-
stroys the effect of the therapy over time. We have chosen the Hill power
to be 8 in equation (41). Choosing it larger does not change the numerical
output significantly and choosing it smaller makes the dormancy state, i.e.
the temporary plateau between year 25 and 40 in figure 10, shorter and
resistance will start a bit earlier. For U = 1, expression (41) takes the satu-
ration value 1
2
D1. This half saturation value corresponds approximately to
year 42 at figurer̃effig:resistance.
Figure 10: Effects of resistance of malignant stem cells to T-cell elimination. The
dotted lines show the cancer development toward the co-existing steady state in absence
of resistance whereas the full lines show the development when resistance develops. Green
curves represent the hematopoietic stem cell counts (X0) and the red curves represent
the malignant stem cell counts (Y0). Parameters are as for figure 4 but with D1 = 10.
Black dotted line shows the inhibiting factor 11+U8 over time, reducing the population
death due to resistance. All quantities are shown in dimensionless units except time
which is in years. See section 5 for further discussion.
A specific finding deserves to be emphasized: A dimensionless stem cell
reproduction ratioR exists, which determines how robust the hematopoietic
condition may be and how disastrously a potential blood cancer disease
will develop. This is similar to the concept of a reproduction number in
epidemiology describing whenever an epidemic outbreak may occur. In our
case, the reproduction ratio consists of a combination of six physiological
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parameters from the dimensional form of the full model. Inspired by the


















Thus for R > 1 we have a more serious situation than for R < 1, showing
that if the reproduction ratio exceeds the threshold R0 = 1 it is more
disastrous than if it is below R0. Physiologically the reproduction ratio R
tells us that the situation is worse if malignant stem cells have a better fitness
than the hematopoietic stem cells. The intuitive interpretation in most bio-
medical literature attributes the main cause for cancer development to the
frequency of stem cell division. Our fitness concept, the ratio between the
self-renewal rate and the sum of the death rate and the proliferation rate, is
far more nuanced, but is in agreement with the literature and furthermore,
which also confirms our results. To force the model from a regime of highly
disastrously development into a regime of less disastrously development we
may simply focus on how to manipulate the reproduction ratio, R, for
the specific system under consideration to become less than the threshold
value of R. The threshold concept depends on six parameters, which offer
independent manipulation possibilities. Alternatively, one may consider the
fitness of hematopoietic cells as a given fitness threshold value for a specific
system. Thus the development of a given mutation is determined by the
fitness value of that mutation compared to that of the hematopoietic cells.
In addition to the primary reproduction ratio R, a secondary reproduc-
tion number, S, important for the dynamics of the system as it appears in















This secondary reproduction number, S, describes the T-cell dependent
fitness of the malignant stem cells relative to the afore defined fitness of
the hematopoietic stem cells, whereas the primary reproduction ratio, R,
compares the T-cell independent fitness of malignant stem cells to that of
hematopoietic stem cells.
Increasing the inflammatory stimuli J accelerates and drives the blood
cancer in general. Vice versa, the blood cancer itself induces an inflam-
matory response, and thus the coupled system introduces a negative spiral
with respect to the disease development. For further details on this see [2].
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5. Discussion and conclusion
A novel mechanism-based model - the Cancitis model - describing the
interaction of blood cancer and the inflammatory system is proposed. The
immune response is divided into two components, one where the elimina-
tion rate of malignant stem cells is independent of the size of the cancer
(Y0-independent death rate) and one where the elimination rate depends
on the size of the cancer (Y0-dependent death rate). The model confirms
that inflammation may accelerate and drive a cancer beyond the fact that
the presence of a cancer induces an inflammatory response. A dimensional
analysis shows that the full 6-dimensional system of nonlinear ordinary dif-
ferential equation may be reduced to a 2-dimensional system - the reduced
Cancitis model. In terms of Fenichel theory this is known as the reduced
model or the slow manifold approximation. This is a very good approxima-
tion and is appropriate for MPNs in particular, since these diseases develop
slowly. The original parameters appear in the reduced model in clusters,
showing the important grouping of parameters. The reduced model allows
for a highly analytical investigation of steady states and their dependence
especially on the inflammatory stimuli J , the Y0-independent death rate
(D0) and the Y0-dependent death rate (D1). A semi-analytic investiga-
tion reveals the stability properties of the steady states. Finally, we prove
positivity of the system and the existence of an attracting trapping region
in the positive octahedron guaranteeing global existence and uniqueness
of solutions. For the reduced Cancitis model the possible topologies are
completely described as having a Janus structure, where two qualitatively
different topologies appear for different sets of parameters given by R. In
the important work by Stiehl et. al. [64] a model without immune in-
teraction is presented. The authors discuss a fraction similar to R given
in equation (42) and shows that it is important for the dynamics of the
system. However, this model involved explicitly the hierarchy of progenitor
cells, whereby a lot of unknown parameter are introduced, thus their results
appear as a more qualitative analysis involving all these parameters. The
relative simplicity of our model, due to the parsimonious principle and the
model reduction, make it possible to state sharp criteria involving R, which
along with another threshold S given in equation (43) deliver a complete
topological analysis of the possible dynamics.
For the default parameters a trivial steady state F0 always exist. Start-
ing by no stimulation J of the inflammatory system only the trival steady
state is stable. Increasing J will turn this trival steady state into an unstable
steady state while a leukemic steady state appears. If J is increased further
an unstable hematopoietic steady state occurs. In absense of mutations,
i.e. no malignant cells, the hematopoietic steady state is stable. Being a
saddle point, a pertubation of the hematopoietic steady state with malig-
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nant cells may cause the state to be repelling away from the hematopoietic
steady state. At the bifurcation the purely leukemic steady state takes over
the stability turning the trivial steady state into an unstable state. Both
the hematopoietic steady state and the leukemic steady state start at the
trivial steady state, and move away from it with increasing values of J . A
co-existing steady state bifurcates from the leukemic one for even higher
values of J and simultaneously the leukemic steady state loses its stabil-
ity. For increasing values of J , the co-existing steady state moves towards
higher X0-values and with only a minor increase in Y0. Increasing D1 also
decreases Y0, thus representing an attractive disease condition compared to
full blown blood cancer.
We emphasize that the choice of default parameter values for Cx and
Cy make the highest order coefficient in equation (B.23), given in expres-
sion (B.24), relatively small, since CxCy ≈ 1. As a consequence not only the
roots of equation (B.23), but also the number of real roots become sensitive
to these parameter values. Thus some caution is needed; A considerable
change in parameters may not only change the stability properties, but also
the number of possible co-existing steady states. The outbreak of blood
cancer in general is commonly considered to occur when the ratio of the
self-renewal rates, R, exceeds a threshold value, frequently taken to be one.
However, the model implies that the ratio between R and the cell death rates
D0 and D1 should rather be considered. In fact, the analysis motivates the
definition of a primary and a secondary reproduction ratio, R and S, respec-
tively, crucially for topology of the dynamics of the system. If R is larger
than one, the leukemic steady state appears first and the hematopoietic
steady state later for increasing J . The leukemic steady state is stable until
the co-existing steady state may take over. If instead, R is less than one, the
hematopoietic steady state appears first and the leukemic steady state later
with respect to increasing J . Thus the hematopoietic steady state is stable
until the co-existing steady state takes over while the leukemic steady state
remains unstable. Inflammation is presumably another important quantity
for the onset and development of blood cancer, greatly influenced by the
inflammatory stimulation J [19, 10, 39, 33, 31, 30, 71, 72, 2, 29]. This sug-
gests that the body may manage initial leukemia as long as the self-renewal
rate is not too high, but fails to manage it if an inflammation appears.
These findings suggest combining treatment with anti-inflammatory treat-
ment. Thus inflammation may trigger and drive blood cancers including
MPNs.
It is interesting that decreasing the inflammatory stimuli for R > 1
may not be a good first step in treatment of such patients. Instead D1
should be increased first and subsequently the inflammatory stimuli may
be reduced. However, for R < 1 the inflammatory stimuli may be reduced
simultaneously with increasing D0.
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. An increase in the rate rx increases the amount
of hematopoietic stem cells, which quickly increases the amount of mature
hematopoietic cells, thus leading to an indirect increases of the amount of
dying cells (for unchanged values of dx0 and ax). An increase in the amount
of dead cells stimulates the inflammation, whereas es eliminates the debris
of the dead cells. Thus increasing the fraction rx/es eventually increases
the inflammation. This may suggest that drugs helping the inflammatory
response in eliminating the debris more effectively may decrease J . How-
ever, the denominator dx0 + ax denotes the rate at which hematopoietic
stem cells are reduced, due to apoptosis and proliferation into progenitor
cells. Hence, an increase in either dx0 or ax will decrease J . The reason
why is that a decrease in x0 in the long term leads to a decrease in x1 and
thus a decrease in the amount of dead cells, a, whereby the inflammatory
response become less stimulated. Hence, treatment affecting the stem cells
by increasing the natural death rate dx0 may decrease the inflammatory
response and thereby help reduce the cancer. In combination, the com-
petition between self-renewal rate rx and the elimination of hematopoietic
stem cells dx0 +ax is reflected in the ratio
rx
dx0+ax
. Likewise, the competition
between the inflammatory load I and the elimination rate of debris by the
immune response es is reflected in the ratio
I
es
. Thus increasing these ratios
increase J . This is surprising, since intuitively one would guess that treat-
ment should primarily affect the malignant stem cells and leave the normal
hematopoietic stem cell as unaffected as possible. Of course, affecting the
amount of normal hematopoietic stem cells has other impacts apart from
just affecting J , due to the direct competition between the cell types. In-
creased J also affect the self-renewal rate for the malignant stem cells. Since
the stem cell self-renewal is proportional to J in both cases, the malignant
cells benefit most, due to an expected higher baseline self-renewal rate of
the malignant stem cells ry than for the normal hematopoietic stem cells
rx.
The specific inclusion of the T-cells in the immune response has its roots
in gene therapy and interferon-α treatment. In gene therapy a patients own
T-cells are modified outside the body and re-injected to fight the cancer.
As shown, it is in principle a very effective instrument, but in practice it
has limited function, since cancer cells almost always develop resistance, by
modifying the recognizable surface receptors used by the naive T-cells to
identify the cancer cells. Without being recognized by naive T-cells, the
effector cells will not attack the cancer cells making this defence weak. In-
terestingly, even if resistance did not occur, the model predicts that T-cell
therapy does not cure the patient, but only keeps the cancer in an iron
grip at the co-existing steady state securing limited growth of cancer for a
while. When resistance occurs the grip loosens and a fatal growth begins
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despite continued T-cell therapy as illustrated on figure 10. The fact is that
increasing D1 by a T-cell therapy may turn a full blown leukemic (stable)
steady state into a co-existing (stable) steady state or even for high dose
therapy into a healthy (stable) hematopoietic steady state temporarily as
illustrated in Figure 7. It takes some years (e.g. 5 years) as illustrated in
Figure 9. However, without changing the parameters permanently (e.g. D1)
the cancer recurs either because the cancerous stem cells are not completely
eradicated or as soon as a new mutation (surviving repair mechanisms) ap-
pears. For a supplementary discussion reaching the same conclusion see
[47]. However, for the case of all cancerous stem cells to be completely
eliminated 20 years of treatment may be needed. In fact, due to the detec-
tion limit, one can never be sure that the cancer is completely eradicated. A
detection limit of 1% of 1010 mature cells (or 104 stem cells) corresponds to
108 mature cells (or 100 stem cells). Thus, to guarantee an eradication the
malignant stem cells requires a detection limit lower than 0.01%. However,
T-cell therapy may be suitable in combination with other treatment.
In the groundbreaking work by Kuznetsov et. al. [41, 42] the intrinsic
dynamics of the cells themselves was not considered, but was simply taken
as logistic growths independent of the other cell types. In contrast to this
we describe the common dynamics of all cell types based on the underlying
biological mechanisms. We include the effect of cancerous cells on normal
cells and vice versa, their interaction with the dead cells, the dead cells
interaction with the immune system, the interaction of the immune system
with the replication of (living) cells, and specifically the interaction between
cancerous cells and the adaptive immune system, mediated by T-cells and
other killer cells. In this way the presented model deviates from the general
models in [54, 18, 53, 59, 17, 8, 34, 58, 28, 50, 51, 4, 32, 23, 3, 36, 48, 49].
Thus co-existing states are explicitly shown to be possible as it is shown
how such states depends on the important parameters, i.e. inflammatory
load and the two relevant death rates. It is shown that in case resistance
is considered, this co-existing state is merely a dormancy state and ulti-
mately develops into the full blown cancer state. It is interesting that our
mechanism-based multi-cell model confirms previous conclusion that im-
munotherapy does not completely eradicate malignant cells predicted by
Kuznetsov et al [41]. This is an important subject as pointed out by [20].
Besides having a strengthening effect on the effector cells, interferon-
α also affects other parts of the cancer-immune system in a constructive
synergistic way, which may make the treatment even more effective. A
full discussion of how various treatments affect blood cancer and treatment
optimization will be addressed in subsequent papers.
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Appendix A. Dimensionless form of six dimensional model
Formulating equations on dimensionless form may reduce the number
of free parameters by grouping the original parameters into clusters of pa-
rameters, the dimensionless parameters. Simultaneously the dimensionless
form may suggest a model reduction using Fenichel theory from geometric
singular perturbation theory [40].
All variables in equation (1) and (2) are scaled by a constant having
the unit of the variable, if any, and it is denoted with same symbol as the
variable, but with a bar above. Likewise, the corresponding dimensionless
variable is denoted with the corresponding capital letter and with index
as the original symbol. Thus we put x0 = x0X0, x1 = x1X1, y0 = y0Y0,
y1 = y1Y1, a = aA, s = sS, and t = tT , with X0, X1, Y0, Y1, A, S, and
T , the dimensionless variables and x0, x1, y0, y1, a, s, and t the scaling
constants carrying the dimensions. Hence the extended model of the dif-
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putting the mutation rate rm to zero and where dy0(Y0) = d̂y0 + d̃y0y0 · Y0.
Here prime denote the derivative with respect to the dimensionless time
variable T . To simplify the hematopoietic steady state EH+ in equation (3),
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∼ 103 day (A.2g)
where the order is stated after the ∼ symbol based on the default parameter
values in table 1. These values are in accordance with those reported in
the literature where they are estimated to obtain observed cell counts, see
[25, 62, 26]. In addition, we have used 700 as a normal number of dead
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∼ 1, and 1
ess
∼ 1−1.
We emphasize that the dimensionless variable X0, X1, Y0, Y1, S and A are
all of the same order, since each are normalized by their ’maximal carying
capacity’.
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Appendix A.1. The reduced extended model - the reduced cancitis model
The system is initially close to the unstable hematopoietic steady state
and the development of MPNs is slow, thus we are interested in the reduced
system. A naive QSSA may be performed but since several time scales
are involved one should be careful. By Fenichel theory the equations (A.3-
A.8) involving small epsilon terms may be studied in the limit of vanishing
left hand sides, whereby we obtain the reduced cancitis model, i.e. the
slow manifold approximation. Thus from equation (A.5-A.6) we obtain the
algebraic relations,
X1 = X0, (A.9a)
Y1 = Y0. (A.9b)
Using this in equation (A.8) gives
ε4A
′ = (2BxX0 + 2ByY0 − AS) (A.10a)
with ε4 = ε2ε3 ∼ 10−13, 2Bx = bx0 +bx1 ≈ bx1 ∼ 10−1, and 2By = by0 +by1 ≈
by1 ∼ 10−1. Thus we will consider By to be independent of Y0 in what
follows.
Thus, from equation (A.7) and (A.10a),
S = J ±
√
J2 + 2BxX0 + 2ByY0 ≡ S± (A.11)
where only S+ is non-negative allowing us to disregard the possibility of
S = S− in what follows and thus by substituting S+ from equation (A.11)




J2 + 2BxX0 + 2ByY0 (A.12)
which is always non-negative and where J = I
2ess
.
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default dimensionless parameter values are listed in table 2 and we note
that all values are of order one. Note, the reduced model involves 8 pa-
rameters (including J) where D1 describe the strength of the Y0 dependent
elimination term in dimensionless form. We emphasize the local existence
and uniqueness of solution in the non-negative octahedron. Subsequently
we will focus on the impact of the dimensionless inflammatory stimuli J .
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Appendix B. Derivations of admissible Steady states
From equation (10a) the hematopoietic steady state FH = (X0, 0)
exist if and only if
J +
√
J2 + 2BxX0 = 1 +X0, (B.1)
i.e. if and only if √
J2 + 2BxX0 = X0 + 1− J. (B.2)
Disregarding the possibility of double roots a solution exist if and only if
J < X0 + 1 (which have to be checked subsequently) given by,
X20 − 2(J +Bx − 1)X0 − (2J − 1) = 0, (B.3)
i.e.
X0 = (J +Bx − 1)±
√
(J +Bx − 1)2 + (2J − 1) (B.4a)
= (J +Bx − 1)±
√
(J +Bx)2 − 2Bx. (B.4b)
These roots are real if and only if J ≥ −Bx +
√
2Bx, a trivial statement
for Bx > 2 or J >
1
2




and JH,2 = 1−Bx we may rewrite equation (B.3) as,
X20 − 2(J − J2)X0 − 2(J − J1) = 0, (B.5a)
Applying Descartes’ rule of signs gives that X0+ > 0 if and only if J >
min{J1, J2} (= 12 for default parameter values) and X0− > 0 if and only if
J2 < J < J1, requiring Bx >
1
2
(which is not the default case).




(J +Bx)2 − 2Bx < Bx, (B.6a)
which is trivially fulfilled for X0+. For X0−, this gives
J < J0 ≡ −Bx +
√
B2x + 2Bx, (B.7)
since J is restricted to be positive for physiological reasons.
Hence, FH+ is admissible if and only if J > min{J1, J2} (= 12 for default
parameter values) while FH− is admissible if and only if
−Bx +
√
2Bx < J < −Bx +
√
B2x + 2Bx (B.8a)
and





i.e. if and only if
−Bx +
√







which is not in accordance with the default parameter values, meaning that
in realistic cases only FH+ may be admissible.
The Purely leukemic steady states are the solutions of g(Y0, J) = 0
with





−D0 −D1Y0 , (B.11)







As g(y, J) is increasing in J , g(0, J) > 0 for J > Jcrit. For any fixed J ,
g(y, J) < 0 for y sufficiently large. Since g is continuous, the intermediate
value theorem ensures that for any fixed J > Jcrit there exists a y satisfying
g(y, J) = 0 i.e. a solution exists to (B.11).







0 + α4Y0 + α5 = 0, (B.13)







































































Note that α1 > 0, α2 > 0. For large J , α3, α4, α5 are all negative so by
Descartes’ rule of sign there is exactly one positive root to the polynomial
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in this case showing that a leukemic steady state is inevitable for large
inflammatory stimuli J .











. The coefficients α3, α4, α5 change






than the root JL,4 of α4(J), which again is smaller than the root JL,3 of
α3(J). This implies that as α5 crosses zero a unique leukemic steady state
is generated and it persists for any larger J values as there is exactly one


















, then α3 remains positive for J > JL,4 while α4
and α5 behave like in the previous case. Contrary to the previous case there
exists a J between JL,4 and JL,5 such that α4 < 0 and α5 > 0. Hence, there
are two sign changes in the coefficients of the polynomial, which indicate 0
or 2 roots. As J is increased such that α5 < 0 there is one sign change in
the coefficients for all larger values of J .
The criterion α5 > 0 thus guarantees a unique, positive root to (B.13).
Since at least one solution to (B.11) exists in this case, the root of the
polynomial must satisfy (B.11).
As the polynomial on the left hand side of (B.13) is decreasing in J and




occurs with a positive slope, an increase in J






Notice, putting g = 0 in equation (B.11) is equivalent to equation (B.18)
with X0 = 0. Thus the leukemic steady state and the co-existing steady
state are equal for X0 = 0. By implicit function theorem it follows that
for Y0 ≥ Y0L the derivative of X0 = X0(Y0) with respect to Y0 is positive
corresponding to an increasing steady state trajectory in J .
From equation (10) co-existing steady states FC = (X0, Y0) having
positive components exist if and only if
J +
√














Assuming solutions exist the equations are equivalent to,









(1 + CxX0 + Y0) (B.18)
and √
J2 + 2BxX0 + 2ByY0 = 1 +X0 + CyY0 − J. (B.19)
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Disregarding the possibility of double roots a solution exist if and only if
1 +X0 + CyY0 > J, (B.20)
and










which have to be checked subsequently.



















for non-vanishing denominator and substituting it into (B.19) gives the
fourth order polynomium in Y0,
η0Y
4
0 + η1(J − JC,1)Y 30 + η2(J − JC,2)Y 20


























































































































































































































































For default values of parameters, equation (B.23) becomes
8.72 · 10−6Y 40 − 3.68 · 10−3(J + 0.61)Y 30
+4.39 · 10−2(J + 1.06)Y 20 + (J − 0.71)Y0 − 4(J − 0.27) = 0. (B.33)
From the default parameters it follows that JC,2 < JC,1 < 0 < JC,4 <
JC,3 < J and by Descartes’ rule of sign there exists one or three positive
and real root if and only if J > JC4. From numeric considerations it follows
that the number of positive Y0-roots are three. However, two of these cause
X0 to be negative in acordance with equations (B.20-B.21). Thus exactly
one co-existing steady state exist.
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T., Goecke, T. W., Rath, B., Germing, U., Marciniak-Czochra, A.
and Wagner, W. [2014]. Feedback Signals in Myelodysplastic Syn-
dromes: Increased Self-Renewal of the Malignant Clone Suppresses
Normal Hematopoiesis, PLoS Computational Biology .
[70] Wilkie, K. [2013]. Systems Biology of Tumor Dormancy. Chapter 10.
A review of mathematical models of cancer-immune interactions in the
context of tumor dormancy, Vol. 734, Springer-Verlag, New York.
[71] Wodarz, D. and Komarova, N. [2014]. World Scientific Publishing.
[72] Zhang, J., Fleischman, A. G., Wodarz, D. and Komarova, N. L. [2017].
Determining the role of inflammation in the selection of JAK2 mutant
cells in myeloproliferative neoplasms, Journal of Theoretical Biology .
50
